Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to over…
Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Lyell Immunopharma, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDLyell Immunopharma, Inc. can't present revenue by segment